Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia
Author:
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Reference28 articles.
1. CD20 a a target for therapeutic type I and II monoclonal antibodies;Beers;Semin Hematol,2010
2. Mechanisms of killing by anti-CD20 monoclonal antibodies;Glennie;Mol Immunol,2007
3. Rituximab in chronic lymphocytic leukemia;Jaglowski;Semin Hematol,2010
4. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma;Keating;Drugs,2010
5. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma;Molina;Annu Rev Med,2008
Cited by 67 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059;Clinical Pharmacokinetics;2024-06-22
2. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma;Clinical and Translational Science;2024-05-29
3. A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo;Brain, Behavior, and Immunity;2024-05
4. Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study;Frontiers in Pharmacology;2024-03-26
5. Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence;Kidney International Reports;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3